(S)-10,11-dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: (S)-10,11-dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid
• 英文别名: 2-[(9S)-14-[3-(pyridin-2-ylamino)propoxy]-9-tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaenyl]acetic acid
• 化学式: C₂₅H₂₆N₂O₃
• 分子量: 402.493
• InChiKey: HODBWQCCKYDYPY-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  71.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-[(3-hydroxy-1-propyl)amino]pyridine-N-oxide 在 palladium on activated charcoal sodium hydroxide 、 三苯基膦 、 环己烯 、 偶氮二甲酸二乙酯 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 生成 (S)-10,11-dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid
  参考文献：
  名称：

  口服生物利用型非肽玻连蛋白受体拮抗剂在骨质疏松症模型中具有功效。

  摘要：

  基于新型碳环Gly-Asp模拟物，发现了一系列新的有效的非肽玻连蛋白受体拮抗剂。该系列的代表产品SB 265123（4）在大鼠中具有100％的口服生物利用度，并且在卵巢切除的骨质疏松大鼠模型中具有口服活性。

  DOI：

  10.1016/s0960-894x(99)00283-8

文献信息

• Vitronectin receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US20020091264A1

  公开（公告）日：2002-07-11

  Compounds of the formula (I) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis: 1 or a pharmaceutically acceptable salt thereof.

  公式（I）的化合物被披露为维特隆蛋白受体拮抗剂，并且在骨质疏松症的治疗中很有用：1或其药用可接受的盐。
• Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
  申请人：Lode Holger N.

  公开号：US20090060864A1

  公开（公告）日：2009-03-05

  The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.

  本发明提供了一种治疗哺乳动物肿瘤和肿瘤转移的方法，包括向需要治疗的哺乳动物施用足够的拮抗剂治疗量，以抑制血管生成，结合足够的抗肿瘤免疫治疗剂量，例如抗肿瘤抗原抗体/细胞因子融合蛋白，其中包括细胞因子和重组免疫球蛋白多肽链，足以引起特定于细胞因子的生物反应。
• Combination therapy using anti-angiogenic agents and TNF-alpha
  申请人：Merck Patent GmbH

  公开号：EP2292251A1

  公开（公告）日：2011-03-09

  The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of anti-angiogenic agents and tumor necrosis factor alpha (TNFα) optionally together with other cytotoxic agents, such as interferon gamma (IFNγ) or chemotherapeutic agents such as cisplatin, or ErbB receptor inhibitors, such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.

  本发明涉及一种治疗肿瘤和肿瘤转移瘤的联合疗法，包括抗血管生成剂和肿瘤坏死因子α（TNFα），可选择与其他细胞毒性药物如γ干扰素（IFNγ）或化疗药物如顺铂、或ErbB受体抑制剂如抗EGFR抗体一起使用。该方法和包含上述药剂的药物组合物可以使每种治疗剂的肿瘤细胞增殖抑制效果产生协同增效作用，从而产生比单独使用一种成分更有效的治疗效果。
• Specific therapy and medicament using integrin ligands for treating cancer
  申请人：Merck Patent GmbH

  公开号：EP2441464A1

  公开（公告）日：2012-04-18

  The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone, concurrently or not in the dosage regime of the present invention.

  本发明涉及一种治疗肿瘤和肿瘤转移瘤的联合疗法，包括整合素配体（最好是整合素拮抗剂）与与所述配体连续给药时具有协同疗效的共同治疗剂或治疗形式（如化疗剂和或放射治疗）一起给药。这种疗法可使每种治疗剂对肿瘤细胞增殖的抑制作用协同增效，从而产生比单独使用一种成分、同时使用或不使用本发明的剂量机制更有效的治疗效果。
• Specific Therapy and Medicament Using Integrin Ligands for Treating Cancer
  申请人：Merck Patent GmbH

  公开号：EP2578225A1

  公开（公告）日：2013-04-10

  The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone, concurrently or not in the dosage regime of the present invention.

  本发明涉及一种治疗肿瘤和肿瘤转移瘤的联合疗法，包括整合素配体（最好是整合素拮抗剂）与与所述配体连续给药时具有协同疗效的共同治疗剂或治疗形式（如化疗剂和或放射治疗）一起给药。这种疗法可使每种治疗剂对肿瘤细胞增殖的抑制作用协同增效，从而产生比单独使用一种成分、同时使用或不使用本发明的剂量机制更有效的治疗效果。